pyrazines has been researched along with glucagon-like peptide 2 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aaboe, K; Deacon, CF; Holst, JJ; Knop, FK; Krarup, T; Madsbad, S; Vilsbøll, T | 1 |
| Askov-Hansen, C; Hartmann, B; Henriksen, DB; Holst, JJ; Jeppesen, PB; Lund, P | 1 |
1 trial(s) available for pyrazines and glucagon-like peptide 2
| Article | Year |
|---|---|
Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Administration Schedule; Female; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glucagon-Like Peptide 2; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Male; Metformin; Middle Aged; Peptide YY; Postprandial Period; Pyrazines; Sitagliptin Phosphate; Triazoles | 2010 |
1 other study(ies) available for pyrazines and glucagon-like peptide 2
| Article | Year |
|---|---|
Effect of glucagon-like peptide-2 exposure on bone resorption: Effectiveness of high concentration versus prolonged exposure.
Topics: Adult; Area Under Curve; Biomarkers; Bone Resorption; Collagen Type I; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Female; Glucagon-Like Peptide 2; Humans; Injections, Intravenous; Injections, Subcutaneous; Male; Middle Aged; Peptide Fragments; Pyrazines; Sitagliptin Phosphate; Triazoles | 2013 |